Trials about this group of obstetric diseases have focused on physiopathology, and there is enough evidence that one of the most important biomarkers for the prediction of PE and IUGR is the PAPP-A [37]; moreover, the screening combined test from the Fetal Medicine Foundation (FMF) group, which uses this gestational protein, is, nowadays, the most accurate methods of prognostication of the pregnancy at first trimester [2, 22, 24, 26, 27, 30, 38–40]. The gene discussed is PAPPA; the disease is fetal growth restriction.